BOSTON, Jan. 28, 2022 /PRNewswire/ -- NeuroBo
Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage
biotechnology company, today announced the appointment of D.
Gordon Strickland to its Board of
Directors, effective as of January 27,
2022. Mr. Strickland will serve as Chair of the Company's
Audit Committee.
"Gordon is a highly accomplished executive with more than 35
years of experience, including many senior leadership positions,"
said Andrew I. Koven, Chairman of
NeuroBo's Board of Directors. "I am pleased to welcome him to the
NeuroBo Board of Directors and look forward to his contributions as
we pursue our next phase of growth and development."
"I am excited to join the NeuroBo Board of Directors at such an
important stage for the Company," said Mr. Strickland. "I look
forward to working with my fellow Directors and the NeuroBo
leadership team as we position the Company for long-term growth and
value creation."
Mr. Strickland has served in numerous leadership roles
throughout his career, including, most recently, as the Chairman of
Ampex Corporation, where he previously served as CEO from
February 2007 until March
2012.
Prior to Ampex, he was the president and CEO of Cardiff Holdings
from March 2012 until August 2013, the chairman of Medical Resources
from September 1997 until
January 2011, the president and CEO
of MCSi, Inc. from March 2003 until
March 2004, the president and CEO of
Capitol Wire, Inc. from September
1999 until August 2002 and had
leadership roles with Kerr Group from June
1986 until August 1997,
including serving as the president and CEO, and as Senior Vice
President, Finance and Chief Financial Officer.
He previously served as a member of the Board of Directors of
eCommission and Applied Technical Services, and as a US Naval
Officer.
Mr. Strickland received a Master of Business Administration,
Finance from the Wharton School of the University of Pennsylvania and a Bachelor of Arts,
Economics from Yale University.
Forward Looking Statements
Any statements in this press release that are not statements of
historical fact constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements include, but are not limited to,
statements regarding NeuroBo's development expenses, the
development of NeuroBo's product candidates and the therapeutic
potential, timing and nature of clinical trials and potential
regulatory approval of NeuroBo's clinical programs and pipeline.
Forward-looking statements are usually identified by the use of
words, such as "believes," "anticipates," "expects," "intends,"
"plans," "may," "potential," "will," "could" and similar
expressions. Actual results may differ materially from those
indicated by forward-looking statements as a result of various
important factors and risks. These factors, risks and uncertainties
include, but are not limited to: recent changes in NeuroBo's
management; the failure to obtain all of the benefits or recognize
all of the synergies anticipated from the ANA acquisition; the
integration of ANA potentially diverting management resources from
operational matters and other strategic opportunities; the effect
of future milestone payments and royalties specified in the ANA
acquisition agreement on the results of operations and financial
position of NeuroBo; the occurrence of health epidemics or
contagious diseases, such as COVID-19, and potential effects on
NeuroBo's business, clinical trial sites, supply chain and
manufacturing facilities; NeuroBo's ability to continue as a going
concern; the timing of completion of NeuroBo's planned clinical
trials, including with respect to ANA001 and Gemcabene; the timing
of the availability of data from NeuroBo's clinical trials,
including with respect to ANA001 and Gemcabene; NeuroBo's
plans to research, develop and commercialize its current and future
product candidates, including the potential alternative pathways
for NB-01; NeuroBo's ability to successfully collaborate with
existing collaborators or enter into new collaborations and to
fulfill its obligations under any such collaboration agreements;
the clinical utility, potential benefits and market acceptance of
NeuroBo's product candidates, including ANA001 and Gemcabene; the
impact of government laws and regulations; NeuroBo's ability to
protect its intellectual property position; and NeuroBo's need for
additional financing to fulfill its stated goals. Please
refer to NeuroBo's most recent annual report on Form 10-K, as well
as NeuroBo's subsequent filings on Form 10-Q and Form 8-K, which
are available on the SEC's website (www.sec.gov), for a full
discussion of the risks and other factors that may impact any
forward-looking statements in this press release. In addition, the
forward-looking statements included in this press release represent
NeuroBo's views as of the date hereof. NeuroBo anticipates that
subsequent events and developments will cause its views to change.
However, while NeuroBo may elect to update these forward-looking
statements at some point in the future, NeuroBo specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing NeuroBo's views as of any
date subsequent to the date hereof.
Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-inc-appoints-d-gordon-strickland-to-its-board-of-directors-301470942.html
SOURCE NeuroBo Pharmaceuticals, Inc.